Balchem (NASDAQ:BCPC) Price Target Raised to $190.00

Balchem (NASDAQ:BCPC) had its price target raised by stock analysts at HC Wainwright from $185.00 to $190.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the basic materials company’s stock. HC Wainwright’s target price would indicate a potential upside of 10.81% from the company’s previous close.

Separately, StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Stock Up 2.5 %

Balchem stock opened at $171.46 on Monday. The firm has a market cap of $5.57 billion, a PE ratio of 46.09, a P/E/G ratio of 5.12 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. The firm’s 50 day moving average price is $171.71 and its two-hundred day moving average price is $163.21. Balchem has a twelve month low of $116.84 and a twelve month high of $186.03.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BCPC. Envestnet Portfolio Solutions Inc. increased its holdings in Balchem by 1.5% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,926 shares of the basic materials company’s stock worth $604,000 after buying an additional 59 shares during the last quarter. Inspire Investing LLC lifted its position in Balchem by 2.7% during the third quarter. Inspire Investing LLC now owns 2,348 shares of the basic materials company’s stock worth $413,000 after purchasing an additional 62 shares during the period. Hsbc Holdings PLC raised its stake in Balchem by 1.5% during the second quarter. Hsbc Holdings PLC now owns 4,915 shares of the basic materials company’s stock worth $757,000 after acquiring an additional 75 shares in the last quarter. Atomi Financial Group Inc. raised its stake in Balchem by 6.1% during the third quarter. Atomi Financial Group Inc. now owns 1,674 shares of the basic materials company’s stock worth $295,000 after acquiring an additional 96 shares in the last quarter. Finally, Xponance Inc. increased its stake in shares of Balchem by 5.2% in the second quarter. Xponance Inc. now owns 2,046 shares of the basic materials company’s stock valued at $315,000 after buying an additional 102 shares during the period. Institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.